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From this linked cohort, all infants born between April 1, 1999 and March 31, 2007
were selected and characteristics of those receiving Palivizumab were described.
Among infants with an indication to receive Palivizumab (i.e. born35 weeks, CHD
or BPD), recipients were compared with non-recipients and determinants of receiv-
ing Palivizumab were examined using logistic regression analyses. RESULTS:
Among the 3321 infants with an indication to receive Palivizumab, only 15% were
recipients. The majority was born32 weeks of gestation and mean age at first use
was 3.1 months. The strongest predictor of receiving Palivizumab was being born
32 weeks (OR 49.1; 95%CI 31.5-76.4). However, among the infants born32 weeks,
still 50% did not receive Palivuzmab. Subanalyses among this group showed that
the likelihood of receiving Palivizumab was higher for infants born in later years,
having respiratory distress syndrome or being hospitalized in the RSV season.
CONCLUSIONS: In the Netherlands, Palivizumab is mostly prescribed to infants
born32 weeks, which is according to Dutch guidelines. Use has increased over the
years. However, not all children addressed in the label indication are receiving
Palivizumab.
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OBJECTIVES: Information on the implementation of national (NVL) and interna-
tional guidelines (GINA and GOLD) for asthma and COPD in German clinical prac-
tice is limited. METHODS: Research on inhaled corticosteroid/long-acting 2-ago-
nists (ICS/LABA) in asthma and COPD in Germany was conducted by a modified
Delphi Process with a panel of physicians (six GPs and four pulmonologists) to
produce 25 consensus statements. RESULTS: Three consensus statements provide
insight into current controversies on ICS/LABA use in German clinical practice.
Consensus on the statement “Early initiation onto ICS/LABA therapy can improve
asthma control and help reduce the rate of exacerbations for patients with persis-
tent asthma who are not sufficiently controlled”, suggests that this is current clin-
ical practice in Germany, consistent with GINA, rather than with the NVL recom-
mendation of doubling the ICS dose. The panel agreed that stepping down LABA in
established ICS/LABA therapy, would lead to loss of control and/or worsening of
symptoms in around 50% of patients. It was agreed that by early initiation of ICS/
LABA in uncontrolled asthma 70–80% of health care resource utilisation could be
avoided. Another statement: “A typical patient that should be initiated on ICS/
LABA has moderate to severe COPD, suffers from symptoms and experiences ex-
acerbations” suggests that clinical practice among German physicians anticipated
the 2011 GOLD guideline, in which initiation of a fixed ICS/LABA combination is
based on combined assessment of COPD severity including exacerbation history
and the presence of symptoms. The panel estimated that timely initiation of ICS/
LABA therapy in COPD patients could prevent 10–40% of unscheduled visits (hos-
pitalisations, emergency room and physician visits). CONCLUSIONS: The results of
this research suggest that early initiation of ICS/LABA therapy could substantially
reduce unscheduled treatment costs in asthma patients, and that timely introduc-
tion of LABA/ICS therapy for COPD patients could substantially reduce both un-
scheduled treatment and hospitalisation costs.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) is a major public
health problem. It is often under-diagnosed and undertreated. Prevalence of COPD
is strongly correlated with smoking habits but it affects non-smokers (including ex-
and passive smokers) also. Early and effective treatment can reduce health care
resource use by decreasing the severity and number of exacerbations. Indacaterol
is an “ultra”-long-acting 2-agonist indicated for long-term maintenance broncho-
dilator treatment of airflow obstruction in patients with COPD. METHODS: We
estimated the prevalence of COPD, and the incidence of exacerbations in a single
hospital district with 200,000 inhabitants (Etelä-Pohjanmaa) in one year. Popula-
tion-based data and smoking habits were utilized. Published indacaterol data were
used to estimate the incidence and severity of exacerbations w/wo medication.
Health care resource use was included from both primary and secondary health
care. RESULTS:The estimated number of COPD patients in the hospital district was
13,700 (prevalence 6.85%, out of which 49% were currently non-smokers and 42% in
working age). The patient population potentially benefiting from treatment (GOLD
stages I-IV), was estimated to be 12,000 (87.6% of all COPD-patients). Within one
year, without medication the number of expected exacerbations was 8,634, 3% of
them were severe (needing hospitalization). Applying data from published inda-
caterol trial, 31% of exacerbations could be avoided by medical treatment. This can
lead to a reduction of inpatient days by 800, and outpatient visits by 2,555 among
this patient population in this hospital district. CONCLUSIONS: Based on the
model, in this hospital district, COPD affects almost 7% of the population. In addi-
tion to elderly heavy smokers, health care workers should be aware of the large
working age non-smoking population with possibility of having COPD. Early detec-
tion and effective treatment of COPD may decrease the number of exacerbations
and consequently reduce the use of health care resources.
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OBJECTIVES: To assess continuity of care and to examine any association between
continuity of care and health outcomes (hospitalization, emergency department
visits, deaths and medical costs in Korea. METHODS: This was a retrospective
cohort study using the Korea National Health Insurance Claim Database. Patients,
40 years of age, who were diagnosed with COPD in 2007 (n49,635) were moni-
tored for four years, until 2010. RESULTS: As continuity of care increased, the risks
of hospitalization, emergency department visits, and deaths decreased, as did
medical costs. Also, variables that had significant affects on continuity level for
COPD patients were gender, age, experience of hospitalization, frequency of am-
bulatory visits, number of institution visited, the type of the main clinics attended,
and Charlson’s score. The correlation analysis regarding continuity levels and odds
ratios of health outcomes for COPD patients produced the following results. In
comparison between the first quartile group and the fourth quartile group of COC,
the fourth quartile group had higher rate of hospitalization by 1.61 (95% CI: 1.51-
1.72), a higher emergency department usage by 1.53 (95% CI: 1.41-1.67), and an
increased death rate by 1.26 (95% CI: 1.02-1.56). The odds of fourth quartile belong-
ing to the high costing group were also higher than first quartile (OR1.54, 95% CI:
1.44-1.64). The associations of COC with health outcomes and costs were stronger
when analysing patients visiting a primary institution, as their main attending
medical institution. CONCLUSIONS: As a result, it is proven that improving the
continuity level reduces the risk of hospitalization, ER visits, deaths and medical
costs in COPD patients. Therefore, policy makers needs to develop and actively
move forward the program to improve the continuity level of care in patients with
COPD, especially for the patients using the primary health care service.
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OBJECTIVES: To assess continuity of care and to examine any association between
continuity of care and health outcomes (hospitalization, emergency department
visits), also effects on medical costs. METHODS: This was retrospective cohort
study using the Korea National Health Insurance Claim Database. Patients, 40
years of age, who were first diagnosed with COPD in 2008 (n34,249) were moni-
tored for the following 2 years at specific index dates. RESULTS: The mean of the
COC was 0.91970.1859 retrospectively. As the continuity of care increased, the
risks of hospitalization and emergency department visits decreased, along with
medical costs. Also, variables that have significant affects on continuity level for
COPD patients were gender, age, experience of hospitalization, frequency of am-
bulatory visits, number of institution visited, type of the main attended clinic, the
first attending medical institution, and Charlson’s score. The correlation analysis
on the continuity levels, and hazard ratios of health outcomes showed the follow-
ing results. Comparing the continuity group by COC, the non-continuity group had
higher rate of hospitalization by 1.70 (95% CI: 1.54-1.87) and an increased emer-
gency department usage by 1.70 (95% CI: 1.46-1.99). The risk of non-continuity
group belonging to the high costing group were also higher than the continuity
group (OR1.54, 95% CI: 1.44-1.64). The associations of COC, with health outcomes
and costs, were stronger when analysing patients visiting primary institution as
opposed to attending main medical institutions. CONCLUSIONS: As a result, it is
proven that to improve continuity level, one needs to reduce the risk of deterio-
rated condition and medical costs in COPD patients. Therefore, the policy makers
need to develop and try actively to alter the program to improve the continuity
level of care in patients with COPD, especially for the patients using primary health
care service.
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OBJECTIVES: To document real world management and resource use for patients
with CF. METHODS: Retrospective, medical chart review in eight CF centres in UK.
A stratified random sample of charts was selected from the cohort of patients 6
years of age with a diagnosis of CF caused by genotypes G551D or DF508 homozy-
gous. The study period covered the most recent two years of complete data. Patient
and clinical characteristics, health care resource and drug usage were extracted.
Categorical variables were described as number and proportion of patients and
continuous variables were summarised using descriptive statistics. RESULTS:Data
for 200 patients (50% female, mean age 19.5) were reviewed, with N63 (32%) hav-
ing G551D genotype. Severity distribution measured using FEV1% was: 40%27,
40% and 70%69 and 70%96 patients respectively. Twenty different health
care professional types provided care. Nearly all patients (N199) had a clinic visit
(mean15.2 per patient, SD9.1, median13), and 23% (N45) having an emer-
gency visit (mean2.4 per patient, SD2.2, median2). For drug usage, IV antibi-
otics (73.5%, N147), nebulised therapy (87.0%, N174), and mucolytic treatment
(74.5%, N149) were frequently used. Pancreatic enzyme treatment was used by
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